Clinical Trials
21 trialsNCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT03735589 2023-11-22
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT04510584 2023-06-06
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
University Health Network, Toronto
Phase 2 Withdrawn
NCT05368506 2023-05-06
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04368130 2022-10-14
SIGNAL
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT03607955 2021-09-29
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT03902379 2021-04-19
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
Rutgers, The State University of New Jersey
Phase NA Withdrawn
NCT02487849 2020-03-04
HIPEC
Krankenhaus Barmherzige Schwestern Linz
Phase 2 Withdrawn
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02050009 2019-02-20
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT02530606 2018-11-28
Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer
Stanford University
Phase NA Withdrawn
NCT02872519 2018-06-06
PET Imaging of Ovarian Carcinoma With 18F-FSPG
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT02833506 2018-05-01
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT00634894 2016-04-20
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02470559 2016-02-17
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT01228942 2014-06-06
A Prospective Trial of COXEN Chemotherapy Prediction
University of Virginia
Phase NA Withdrawn
NCT01131039 2013-12-20
Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Emory University
Phase 2 Withdrawn
NCT01982487 2013-12-18
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT01661868 2012-08-21
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Withdrawn